Comparative analysis of Bayer wide-range C-reactive protein (wr-CRP) and the Dade-Behring high sensitivity C-reactive protein (hs-CRP) in patients with inflammatory bowel disease

Journal of Digestive Diseases

Volumn 9, Issue 3, 2008, Pages 140-143

  Maharshak, Nitsan ^a   Arbel, Yaron ^a   Gal Oz, Amir ^a   Rogowski, Ori ^a   Shapira, Itzhak ^a   Berliner, Shlomo ^a   Vered, Yaffa ^a   Canaani, Jonathan ^a   Dotan, Iris ^a  

^a TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

Author keywords

Biomarker; C reactive protein; Inflammatory bowel disease

Indexed keywords

ANTIBIOTIC AGENT; AZATHIOPRINE; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CIPROFLOXACIN; MERCAPTOPURINE; MESALAZINE; METRONIDAZOLE; STEROID;

ADULT; ARTICLE; COMPARATIVE STUDY; CORRELATION ANALYSIS; CROHN DISEASE; DISEASE ACTIVITY; DISEASE DURATION; ENTERITIS; HEALTH CARE COST; HUMAN; LABORATORY TEST; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN DETERMINATION; REMISSION; ULCERATIVE COLITIS;

ADULT; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; COLITIS, ULCERATIVE; CROHN DISEASE; HUMANS; IMMUNOLOGIC TECHNIQUES; NEPHELOMETRY AND TURBIDIMETRY;

EID: 48249110695     PISSN: 17512972     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1751-2980.2008.00335.x     Document Type: Article

References (19)

1. Ghosh S, Goldin E, Gordon FH et al. Natalizumab for active Crohn's disease. N Engl J Med 2003; 348: 24-32.
2. Gordon FH, Hamilton MI, Donoghue S et al. A pilot study of treatment of active ulcerative colitis with Natalizumab, a humanized monoclonal antibody to alpha-4 integrin. Aliment Pharmacol Ther 2002; 16: 699-705.
3. Pepys MB, Hirschfield GM. C-reactive protein: A critical update. J Clin Invest 2003; 111: 1805-12.
4. Vermeire S, Van Assche G, Rutgeerts P. Laboratory markers in IBD. Useful, magic, or unnecessary toys? Gut 2006; 55: 426-31.
5. Solem CA, Loftus EV Jr, Tremaine WJ, Harmsen WS, Zinsmeister AR, Sandborn WJ. Correlation of C-reactive protein with clinical, endoscopic, histologic, and radiographic activity in inflammatory bowel disease. Inflamm Bowel Dis 2005; 11: 707-12.
6. Ridker PM. Cardiology patient page. C-reactive protein: A simple test to help predict risk of heart attack and stroke. Circulation 2003; 108: e81-5.
7. Shenhar-Tsarfaty S, Ben Assayag E, Bova I et al. Wide-range C-reactive protein efficacy in acute ischemic stroke patients. Acta Neurol Scand 2006; 114: 29-32.
8. Rogowski O, Vered Y, Shapira I, Hirsh M, Zakut V, Berliner S. Introducing the wide range C-reactive protein (wr-CRP) into clinical use for the detection of microinflammation. Clin Chim Acta 2005; 358: 151-8.
9. Arbel Y, Eros Y, Rogowski O et al. Comparison of values of wide-range C-reactive protein to high-sensitivity C-reactive protein in patients undergoing coronary angiography. Am J Cardiol 2007; 99: 1504-6.
10. Best WR, Becktel JM, Singleton JW. Rederived values of the eight coefficients of the Crohn's disease activity index (CDAI). Gastroenterology 1979; 77: 843-6.
11. Best WR, Becktel JM, Singleton JW, Kern F Jr. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology 1976; 70: 439-44.
12. Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med 1987; 317: 1625-9.
13. Conroy CA, Cattell R. Infliximab treatment for Crohn's disease. Postgrad Med J 2001; 77: 436-40.
14. Rutgeerts P, Sandborn WJ, Feagan BG et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005; 353: 2462-76.
15. Rifai N, Tracy RP, Ridker PM. Clinical efficacy of an automated high-sensitivity C-reactive protein assay. Clin Chem 1999; 45: 2136-41.
16. Chamouard P, Richert Z, Meyer N, Rahmi G, Baumann R. Diagnostic value of C-reactive protein for predicting activity level of Crohn's disease. Clin Gastroenterol Hepatol 2006; 4: 882-7.
17. Danesh J, Wheeler JG, Hirschfield GM et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 2004; 350: 1387-97.
18. Labarrere CA, Zaloga GP. C-reactive protein. from innocent bystander to pivotal mediator of atherosclerosis. Am J Med 2004; 117: 499-507.
19. Pepys MB, Hirschfield GM, Tennent GA et al. Targeting C-reactive protein for the treatment of cardiovascular disease. Nature 2006; 440: 1217-21.